by Lynde Langdon
Posted 8/18/17, 11:05 am
EpiPen maker Mylan will pay a $465 million settlement for overbilling Medicaid for its emergency allergy injectors for a decade. The Justice Department said Mylan improperly classified its products as generic to avoid paying a higher rebate to Medicaid. The drugmaker also failed to pay Medicaid back for cost increases over the inflation rate, something required by law. Mylan has repeatedly hiked the price of EpiPens, which deliver medication to people having life-threatening allergic reactions.